Aerocrine: UK Clinical Study Demonstrates That Asthma Tests Can Identify Non-Adherence to Medication
Published: Dec 17, 2012
SOLNA, Sweden--(BUSINESS WIRE)--Aerocrine AB (OMX Nordic Exchange: AERO) announces that a clinical trial published in The American Journal of Respiratory and Critical Care Medicine shows that FeNO-testing is an excellent tool to identify patients that don’t adhere to treatment. The American Journal of Respiratory and Critical Care Medicine published on December 1, 2012, the results of a clinical study done at Queen’s University in Belfast, Northern Ireland. The results show how fractional exhaled nitric oxide (FeNO) measurement is an excellent tool for identifying patients who did not use their prescribed inhaled corticosteroids, i.e. did not adhere to treatment. Identifying non-adherence to medication is important because it allows improved patient characterization and tailoring of asthma management to individual needs, which, in turn, results in better patient outcomes at lower cost. Aerocrine’s patented FeNO test, with the NIOX MINO® device, was used in the study. The UK study is entitled: The Utility of Fractional Exhaled Nitric Oxide Suppression in Identification of Nonadherence in Difficult Asthma; its purpose was to identify a test for non-adherence using fractional exhaled nitric oxide (FeNO) suppression after directly observed inhaled corticosteroid treatment. The study concluded that the FeNO suppression test can identify whether or not patients use their inhaled corticosteroid therapy properly and if patients, who fill their prescriptions, took their medicine. Non-adherence is common and ranges from 35–65%.